What's in Renovo's pipeline?

Renovo has 11 drugs in our index: 0 marketed, 0 filed, 2 in Phase 3, 3 in Phase 2, 5 in Phase 1.

Which companies overlap with Renovo's portfolio?

Top competitors by shared drug class: Dompé Farmaceutici S.p.A.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/renovo.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-06-10 · How we verify

Renovo — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Renovo pipeline: 0 marketed, 0 filed, 2 Phase 3, 3 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 2 Phase 3 3 Phase 2 5 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
estradiol (Zesteem)	estradiol (Zesteem)	phase 3	estrogen receptor agonist	estrogen receptor	Women's Health
Juvista (Avotermin)	Juvista (Avotermin)	phase 3	Recombinant growth factor	TGF-β3 (Transforming Growth Factor Beta-3)	Dermatology / Wound Healing

Therapeutic area mix

Other · 4
Dermatology / Wound Healing · 1
Women's Health · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Dompé Farmaceutici S.p.A · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Renovo:

Cite this brief

Drug Landscape (2026). Renovo — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/renovo. Accessed 2026-06-10.